The studies are being presented this week at the AMP 2017 Annual Meeting in Salt Lake City, Utah, where QIAGEN also will demonstrate the GeneReader and other Sample to Insight solutions.
Studies at AMP 2017 demonstrate unique user experiences and high performance of new assays and workflows for multiple sample types |
| [14-November-2017] |
|
HILDEN, Germany and GERMANTOWN, Maryland, November 14, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) today announced new studies highlighting the outstanding analytical performance and ease of use of the GeneReader NGS System, the world's first complete Sample to Insight solution for next-generation sequencing. The studies are being presented this week at the Association for Molecular Pathology (AMP) 2017 Annual Meeting in Salt Lake City, Utah, where QIAGEN also will demonstrate the GeneReader and other Sample to Insight solutions. Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-14-GeneReader_AMP?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-11-14-GeneReader_AMP?sc_lang=en Contacts: QIAGEN Investor Relations
John Gilardi
+49-2103-29-11711
e-mail: ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com
SOURCE Qiagen N.V. |
||
Company Codes: Frankfurt:QIA, NASDAQ-NMS:QGEN, Bloomberg:QGEN@US, Bloomberg:QIA@GR, RICS:QGEN.F, ISIN:NL0000240000 |
